Most expensive medicine: Glybera breaks Guinness world record
Amsterdam, The Netherlands -- Glybera, developed by private Dutch firm uniQure, the first gene therapy to win approval in the West, is expected to arrive soon with a price tag of more than a million dollars, setting the new world record for the Most expensive medicine, according to the World Record Academy: www.worldrecordacademy.com/.most expensive medicine Glybera sets world record
Glybera will cost around £1 million ($1.6 million) per patient, a new world record for pricey modern medicines.
The Guinness world record for the most blood pressure readings taken in 8 hours is 8,026 and was achieved by Iglesia Ni Cristo (Philippines), at Parola Tondo Metro Manila, in Manila, Philippines.
Guinness World Records also recognized the world record for the largest mosquito repellent patch; it measures 3 metres long and 3 metres high (9 ft 10 × 9ft 10 in) and was manufactured by Luxembourg Medicine Co. Ltd. (China).
Glybera is the first gene therapy approval in an independently regulated healthcare market.
Professor John Kastelein, of the University of Amsterdam, said the therapy would have a 'dramatic impact' on patients.
Glybera is expected to arrive soon with a price tag of more than a million dollars, eclipsing the likes of Alexion's ($ALXN)
Soliris, which costs $440,000 a year.
Joern Aldag, chief executive of Amsterdam-based uniQure, said more such treatments would follow and argued a high price was justified because gene therapy restored natural body function and was not just a short-term fix.
The treatment uses a virus to counteract LPLD, lipoprotein lipase deficiency, which can led to acute inflammation of the pancreas.
LPLD affects about one in a million people, leaving them without a vital gene that breaks down fat particles in their blood.
It means fat builds up in the blood leading to abdominal pain and life-threatening inflammation of the pancreas (pancreatitis). The only other way to manage the disease is by having a very low-fat diet.
The therapy uses a virus to infect muscle cells with a working copy of the gene.
Rare or so-called orphan diseases are winning unprecedented attention from drug developers. More than a quarter of the 39 new medicines approved in the United States last year were designated for such conditions.
Tidak ada komentar:
Posting Komentar